RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2023 -- Pappas Capital, a leading investor in next-generation life science and technology companies, announced today that Nick Pappas (no relation) has joined the firm as...
Aclara developed microfluidic lab-on-a-chip technology with applications for genomics, high-throughput drug screening and clinical diagnostics. The company’s technology substantially enlarged throughput capacity while dramatically lowering costs compared with competing approaches. The cornerstone of Aclara’s product development strategy was a disposable plastic or glass “chip” called a LabCard that enabled the computerized control of the movement, measurement and mixing of liquids without the use of moving parts or valves.
Aclara Biosciences
Mountain View, CA
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.